Home > Products > CD28 & EGFR
> Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (VHH-IgG)
Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (VHH-IgG) (CAT#: BSSG-367)
Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-EGFR antibody variable domain are respectively connected to the N terminus of the anti-CD28 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (VHH-IgG) (BSSG-367). Click the button below to contact us or submit your feedback about this product.